Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Company Timeline (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat
AZN Share
Trades13,916
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
AZN Company
Research
AZN Company
Timeline
Share Price Information for Astrazeneca (AZN)
Last checked at -
Last checked at 
Intraday Astrazeneca Share Chart
Latest Timeline Updates for Astrazeneca
AZN
NewsLONDON BROKER RATINGS: JPMorgan cuts ITV to neutral after Sky deal
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday:
AZN
NewsBritain's FTSE 100 slips as miners, healthcare losses weigh
* FTSE 100 down 0.3%, FTSE 250 down 0.2%
AZN
NewsLONDON MARKET CLOSE: Stocks mixed as weak miners weigh in muted trade
(Alliance News) - The FTSE 100 gave back early gains on Monday as falls in gold miners and AstraZeneca, plus soft construction figures, dampened early enthusiasm.
AZN
NewsLONDON BROKER RATINGS: HSBC raises GSK; RBC cuts Close Brothers
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday :
AZN
NewsLONDON MARKET CLOSE: FTSE 100 up as US jobs data eases rate hike fears
(Alliance News) - European stocks soared on Thursday as weaker than expected US jobs figures dampened market worries of a near-term interest rate hike across the pond.
AZN
NewsHutchmed drug approved in China for advanced gastric cancer
(Alliance News) - Hutchmed China Ltd on Thursday announced regulatory approval for savolitinib, brand name 'ORPATHYS', for a form of gastric cancer with "a very poor prognosis".
AZN
NewsAstraZeneca signs CSPC China deal for experimental kidney disease drugs
July 2 (Reuters) - AstraZeneca has entered into a deal worth up to $1.77 billion with CSPC Pharmaceutical Group to discover and develop experimental medicines with the potential to treat kidney d...
AZN
NewsWINNERS & LOSERS: PPHE Hotel ends sales process; CMC Markets rises
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Thursday.
AZN
NewsLondon's FTSE 100 inches lower as Middle East concerns weigh
July 1 (Reuters) - The UK's blue-chip FTSE 100 slipped on Wednesday, with healthcare and energy shares leading declines, as investors monitored the latest setback in U.S.-Iran talks.
AZN
RNSAZN
RNSAZN
NewsLONDON BROKER RATINGS: Deutsche ups RS to buy; Exane neutral on Segro
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:
AZN
NewsAstraZeneca's Enhertu wins first EU tumour-agnostic approval for HER2
(Alliance News) - AstraZeneca PLC on Monday said the European Commission has approved Enhertu as the first tumour-agnostic HER2-directed therapy and antibody drug conjugate in the EU for previously tr...
AZN
NewsLONDON BRIEFING: BT, Verizon merge international arms in joint venture
(Alliance News) - BT and Verizon form international joint venture, Foresight increases its dividend while Plus500 adds to its US prediction markets offering with sports event-based contracts.
AZN
RNSAZN
NewsAstraZeneca's Datroway and Enhertu candidates receive EU approval
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its breast cancer therapy Datroway has been recommended for approval in the EU as a first‑line monotherapy for adults with unresectab...
AZN
RNSAZN
Broker RatingDate:
26-Jun-26
Broker:
Jefferies
Recommendation:
Buy
Old Target:
18,000.00
New Target:
18,000.00
Rating Type:
Reiteration
AZN
Broker RatingDate:
26-Jun-26
Broker:
Deutsche
Recommendation:
Sell
Old Target:
11,500.00
New Target:
11,500.00
Rating Type:
Reiteration
AZN
NewsAstraZeneca's, Daiichi's Datroway recommended for further EU approval
(Alliance News) - AstraZeneca PLC on Friday said the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of Datroway for a form of breast cancer.
AZN
NewsUS military requires flu vaccine for some after outbreak in Texas training center
June 24 (Reuters) - The U.S. military has resumed requiring flu vaccines for some service members in an exception to Defense Secretary Pete Hegseth's guidance declaring the shots voluntary two mo...
AZN
NewsLONDON MARKET CLOSE: Miners peg back FTSE 100 while mid-caps struggle
(Alliance News) - The FTSE 100 edged lower on Tuesday held back by weak miners, while fresh US tech falls and soft UK economic data added to the muted mood.
AZN
NewsWINNERS & LOSERS: Telecom Plus cuts dividend, warns on profit
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Tuesday.
AZN
NewsGLOBAL MARKETS-Stocks dip after US-Iran peace talks delay; yen nears 40-year lows
* Vance pulls out of Friday talks with Iran, oil erases earlier losses
AZN
NewsWINNERS & LOSERS: Broker downgrade hits Admiral; PPHE bid collapses
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Friday.
AZN
NewsModerna's mRNA flu vaccine backed by FDA advisers
* FDA advisers back mFlusiva's benefits for adults 50 and up
AZN
Broker RatingDate:
11-Jun-26
Broker:
Deutsche
Recommendation:
Sell
Old Target:
11,500.00
New Target:
11,500.00
Rating Type:
Reiteration
AZN
NewsAstrazeneca secures US approval for Truqap combo in PTEN‑deficient prostate cancer
(Sharecast News) - Drugmaker Astrazeneca said on Monday that its cancer drug Truqap, used with abiraterone and prednisone, has been approved in the US as the first targeted treatment for a form of adv...
AZN
NewsAstraZeneca's Ultomiris wins US FDA priority review in kidney disease
(Alliance News) - AstraZeneca PLC on Monday said the US Food & Drug Administration has accepted and granted priority review to a supplemental biologics licence application for Ultomiris as a treatment...
AZN
RNSAZN
NewsAstraZeneca says Truqap combination approved in US for prostate cancer
(Alliance News) - AstraZeneca PLC on Friday said a Truqap combination has been approved by the US Food & Drug Administration as a first and only targeted treatment for PTEN-deficient metastatic hormon...
AZN
NewsLONDON MARKET CLOSE: FTSE soars on peace hope as SpaceX IPO blasts off
(Alliance News) - The FTSE 100 ended the week on the front foot as Iran claimed a deal with the US has "never been closer", while investors were glued to dealing screens as trading in SpaceX kicked of...
AZN
NewsProject Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
* Deal deepens oncology push under CEO Luke Miels
AZN
NewsProject Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
* Deal deepens oncology push under CEO Luke Miels
AZN
NewsPfizer CEO warns German investment at risk over drug pricing policies
LONDON/FRANKFURT, June 10 (Reuters) - Pfizer is reviewing the timing and scope of planned investments in Germany, CEO Albert Bourla said in a letter to Chancellor Friedrich Merz, the latest drugmak...
AZN
NewsFOCUS-Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
* Tolerability remains key challenge, with most GLP-1 drugs causing significant side effects
Follow the stocks
